Aytu BioPharma Inc. (NASDAQ:AYTU) Given Consensus Rating of “Hold” by Analysts

Shares of Aytu BioPharma Inc. (NASDAQ:AYTU – Get Free Report) have received a consensus rating of “Hold” from the five analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $9.3333.

A number of research firms have recently weighed in on AYTU. Wall Street Zen raised Aytu BioPharma to a “hold” rating in a research note on Saturday, February 7th. Zacks Research raised Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Wednesday, April 8th.

Get Aytu BioPharma alerts:

View Our Latest Research Report on AYTU

Institutional Investors Weigh In On Aytu BioPharma

A number of hedge funds and other institutional investors have recently modified their holdings of AYTU. Arete Wealth Advisors LLC purchased a new position in Aytu BioPharma during the 1st quarter valued at about $135,000. Dimensional Fund Advisors LP increased its holdings in Aytu BioPharma by 23.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 43,585 shares of the company’s stock valued at $119,000 after purchasing an additional 8,222 shares during the period. XTX Topco Ltd purchased a new position in Aytu BioPharma during the 4th quarter valued at about $67,000. Diadema Partners LP increased its holdings in Aytu BioPharma by 12.1% during the 4th quarter. Diadema Partners LP now owns 305,788 shares of the company’s stock valued at $795,000 after purchasing an additional 33,118 shares during the period. Finally, Persistent Asset Partners Ltd increased its holdings in Aytu BioPharma by 27.2% during the 4th quarter. Persistent Asset Partners Ltd now owns 79,415 shares of the company’s stock valued at $206,000 after purchasing an additional 16,963 shares during the period. Institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Trading Down 0.5%

NASDAQ AYTU opened at $2.18 on Wednesday. Aytu BioPharma has a 1-year low of $1.46 and a 1-year high of $3.07. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 0.27. The stock has a 50-day moving average of $2.50 and a 200-day moving average of $2.44. The firm has a market cap of $23.40 million, a PE ratio of -0.48 and a beta of 0.28.

Aytu BioPharma (NASDAQ:AYTU – Get Free Report) last released its earnings results on Wednesday, May 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.09). Aytu BioPharma had a negative net margin of 60.17% and a negative return on equity of 69.93%. The company had revenue of $12.41 million during the quarter, compared to the consensus estimate of $12.05 million. As a group, sell-side analysts forecast that Aytu BioPharma will post -0.69 EPS for the current year.

About Aytu BioPharma

(Get Free Report)

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.

Read More

• Five stocks we like better than Aytu BioPharma
• Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
• 2 Aluminum Stocks Poised for Big Tariff-Related Gains
• AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
• AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus

Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.